{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:15:47Z","timestamp":1788520547887,"version":"build-2803163510"},"reference-count":160,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Monoclonal antibodies targeting specific cell surface antigens have emerged as a promising therapeutic approach for acute myeloid leukemia (AML), thus widening the treatment landscape of this heinous disease. These antibodies have been designed to selectively target and eliminate leukemic cells while limiting damage to the normal hematopoietic counterpart. Among the potential targets on AML cells, CD33, CD123, and CD47 have shown the major potential in preclinical and clinical trials. Additionally, conjugation of monoclonal antibodies with cytotoxic agents has further enhanced their therapeutic efficacy. Nonetheless, challenges such as antigen heterogeneity, resistance mechanisms, and the immunosuppressive tumor microenvironment remain significant barriers to achieving durable remission in AML patients. This review explores the mechanisms of action, current clinical developments, and ongoing trials into the role of monoclonal antibodies in AML, highlighting their potential to improve clinical outcomes when used alone or in combination with conventional therapies, making them thus able to become, in the near future, a cornerstone in the treatment of AML.<\/jats:p>","DOI":"10.3390\/ijms26104571","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T10:58:07Z","timestamp":1747047487000},"page":"4571","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Monoclonal Antibodies Against Myeloid Leukemia Cells: Current Knowledge and Future Directions"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1663-4468","authenticated-orcid":false,"given":"Daniela","family":"Damiani","sequence":"first","affiliation":[{"name":"Division of Hematology and Stem Cell Transplantation, Udine University Hospital, 33100 Udine, Italy"},{"name":"Department of Medicine, University of Udine, 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9449-2621","authenticated-orcid":false,"given":"Mario","family":"Tiribelli","sequence":"additional","affiliation":[{"name":"Division of Hematology and Stem Cell Transplantation, Udine University Hospital, 33100 Udine, Italy"},{"name":"Department of Medicine, University of Udine, 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of aml in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S247","DOI":"10.1016\/S2152-2650(22)01289-7","article-title":"Aml-402 global epidemiology and impact of genetic variants in adult patients with newly diagnosed or relapsed\/refractory acute myeloid leukemia or myelodysplastic syndrome: A targeted literature review","volume":"22","author":"Monga","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: Current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.clml.2021.05.016","article-title":"Acute myeloid leukemia: Historical perspective and progress in research and therapy over 5 decades","volume":"21","author":"Kantarjian","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","article-title":"High-dose daunorubicin in older patients with acute myeloid leukemia","volume":"361","author":"Lowenberg","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1182\/blood.V88.8.2841.bloodjournal8882841","article-title":"A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A southwest oncology group study","volume":"88","author":"Weick","year":"1996","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1182\/blood.V87.5.1710.1710","article-title":"A randomized study of high-dose cytarabine in induction in acute myeloid leukemia","volume":"87","author":"Bishop","year":"1996","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","article-title":"Optimization of chemotherapy for younger patients with acute myeloid leukemia: Results of the medical research council aml15 trial","volume":"31","author":"Burnett","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199410063311402","article-title":"Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and leukemia group b","volume":"331","author":"Mayer","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/cncr.21543","article-title":"High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials","volume":"107","author":"Kern","year":"2006","journal-title":"Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1200\/JCO.2013.51.8571","article-title":"High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: Results of the eortc-gimema aml-12 trial","volume":"32","author":"Willemze","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1182\/bloodadvances.2018026625","article-title":"Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early cr in adult aml","volume":"3","author":"Bassan","year":"2019","journal-title":"Blood Adv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.leu.2403336","article-title":"Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase iii study","volume":"18","author":"Holowiecki","year":"2004","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1182\/blood.V93.8.2478","article-title":"Randomized phase ii study of fludarabine + cytosine arabinoside + idarubicin +\/\u2212 all-trans retinoic acid +\/\u2212 granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome","volume":"93","author":"Estey","year":"1999","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e20094","DOI":"10.1097\/MD.0000000000020094","article-title":"The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials","volume":"99","author":"Wang","year":"2020","journal-title":"Medicine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","article-title":"Hematopoietic stem cell transplantation for patients with aml in first complete remission","volume":"127","author":"Cornelissen","year":"2016","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Loke, J., Buka, R., and Craddock, C. (2021). Allogeneic stem cell transplantation for acute myeloid leukemia: Who, when, and how?. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.659595"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s12185-018-2412-8","article-title":"Hematopoietic stem cell transplantation for acute myeloid leukemia","volume":"107","author":"Takami","year":"2018","journal-title":"Int. J. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1200\/JCO.2013.52.3480","article-title":"Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia","volume":"32","author":"Pastore","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Research Network, Ley, T.J., Miller, C., Ding, L., Raphael, B.J., Mungall, A.J., Robertson, A., Hoadley, K., Triche, T.J., and Laird, P.W. (2013). Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med., 368, 2059\u20132074.","DOI":"10.1056\/NEJMoa1301689"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3322\/caac.21873","article-title":"Acute myeloid leukemia management and research in 2025","volume":"75","author":"Kantarjian","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_25","first-page":"659","article-title":"Probable clonal origin of acute myeloblastic leukemia following radiation and chemotherapy of colon cancer","volume":"52","author":"Wiggans","year":"1978","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1146\/annurev.me.30.020179.001031","article-title":"Clonal origin of human tumors","volume":"30","author":"Fialkow","year":"1979","journal-title":"Annu. Rev. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/367645a0","article-title":"A cell initiating human acute myeloid leukaemia after transplantation into scid mice","volume":"367","author":"Lapidot","year":"1994","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm0797-730","article-title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","volume":"3","author":"Bonnet","year":"1997","journal-title":"Nat. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/nbt1350","article-title":"Chemotherapy-resistant human aml stem cells home to and engraft within the bone-marrow endosteal region","volume":"25","author":"Ishikawa","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nature14131","article-title":"Exit from dormancy provokes DNA-damage-induced attrition in haematopoietic stem cells","volume":"520","author":"Walter","year":"2015","journal-title":"Nature"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/nm.4210","article-title":"Dnmt3a mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling","volume":"22","author":"Guryanova","year":"2016","journal-title":"Nat. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","article-title":"Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism","volume":"7","author":"Farge","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1158\/2159-8290.CD-20-1375","article-title":"Chemotherapy induces senescence-like resilient cells capable of initiating aml recurrence","volume":"11","author":"Duy","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"17ra19","DOI":"10.1126\/scitranslmed.3000349","article-title":"Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells","volume":"2","author":"Saito","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.leukres.2014.03.007","article-title":"N-cadherin and tie2 positive cd34(+)cd38(\u2212)cd123(+) leukemic stem cell populations can develop acute myeloid leukemia more effectively in nod\/scid mice","volume":"38","author":"Qiu","year":"2014","journal-title":"Leuk. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41375-019-0522-9","article-title":"Targeting cell membrane hdm2: A novel therapeutic approach for acute myeloid leukemia","volume":"34","author":"Wang","year":"2020","journal-title":"Leukemia"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.1073\/pnas.80.19.6126","article-title":"Monoclonal antibodies distinguish phosphorylated and nonphosphorylated forms of neurofilaments in situ","volume":"80","author":"Sternberger","year":"1983","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1084\/jem.174.3.613","article-title":"Antibodies that are specific for a single amino acid interchange in a protein epitope use structurally distinct variable regions","volume":"174","author":"Stark","year":"1991","journal-title":"J. Exp. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2005.01.001","article-title":"Immunogenicity of engineered antibodies","volume":"36","author":"Hwang","year":"2005","journal-title":"Methods"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for mrd-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","article-title":"Blinatumomab added to chemotherapy in infant lymphoblastic leukemia","volume":"388","author":"Kotecha","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of b cells in vivo by a chimeric mouse human monoclonal antibody to cd20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"ref_44","first-page":"1311","article-title":"Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model","volume":"1","author":"Goldstein","year":"1995","journal-title":"Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","article-title":"B cell depletion as a novel treatment for systemic lupus erythematosus: A phase i\/ii dose-escalation trial of rituximab","volume":"50","author":"Looney","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/321522a0","article-title":"Replacing the complementarity-determining regions in a human antibody with those from a mouse","volume":"321","author":"Jones","year":"1986","journal-title":"Nature"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1073\/pnas.95.4.1574","article-title":"The variable domain of nonassembled ig light chains determines both their half-life and binding to the chaperone bip","volume":"95","author":"Skowronek","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","first-page":"634","article-title":"The half-lives of igg subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin","volume":"112","author":"Mankarious","year":"1988","journal-title":"J. Lab. Clin. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.copbio.2011.06.012","article-title":"Strategies for extended serum half-life of protein therapeutics","volume":"22","author":"Kontermann","year":"2011","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nprot.2011.448","article-title":"Expression of high-affinity human antibody fragments in bacteria","volume":"7","author":"Rouet","year":"2012","journal-title":"Nat. Protoc."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Liu, R., Oldham, R.J., Teal, E., Beers, S.A., and Cragg, M.S. (2020). Fc-engineering for modulated effector functions-improving antibodies for cancer treatment. Antibodies, 9.","DOI":"10.3390\/antib9040064"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"10879","DOI":"10.1073\/pnas.1202866109","article-title":"General strategy for the generation of human antibody variable domains with increased aggregation resistance","volume":"109","author":"Dudgeon","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.molimm.2015.04.002","article-title":"Mechanisms of action of therapeutic antibodies for cancer","volume":"67","author":"Redman","year":"2015","journal-title":"Mol. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Vidarsson, G., Dekkers, G., and Rispens, T. (2014). Igg subclasses and allotypes: From structure to effector functions. Front. Immunol., 5.","DOI":"10.3389\/fimmu.2014.00520"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Golay, J., and Taylor, R.P. (2020). The role of complement in the mechanism of action of therapeutic anti-cancer mabs. Antibodies, 9.","DOI":"10.3390\/antib9040058"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"ref_57","first-page":"451","article-title":"Immune checkpoint inhibitors: Breakthroughs in cancer treatment","volume":"21","author":"Kong","year":"2024","journal-title":"Cancer Biol. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"113365","DOI":"10.1016\/j.intimp.2024.113365","article-title":"A comprehensive review of immune checkpoint inhibitors for cancer treatment","volume":"143","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/ncomms1608","article-title":"Competition for fcrn-mediated transport gives rise to short half-life of human igg3 and offers therapeutic potential","volume":"2","author":"Stapleton","year":"2011","journal-title":"Nat. Commun."},{"key":"ref_60","first-page":"7","article-title":"Improving effector functions of antibodies for cancer treatment: Enhancing adcc and cdc","volume":"3","author":"Natsume","year":"2009","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/cbdd.12085","article-title":"Antibody-drug conjugates for the treatment of cancer","volume":"81","author":"Flygare","year":"2013","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1038\/s41467-022-31601-z","article-title":"Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy","volume":"13","author":"Hingorani","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: The \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload diversification: A key step in the development of antibody-drug conjugates","volume":"16","author":"Conilh","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1634\/theoncologist.2019-0370","article-title":"Contextualizing the use of moxetumomab pasudotox in the treatment of relapsed or refractory hairy cell leukemia","volume":"25","author":"Kreitman","year":"2020","journal-title":"Oncologist"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Parakh, S., Lee, S.T., Gan, H.K., and Scott, A.M. (2022). Radiolabeled antibodies for cancer imaging and therapy. Cancers, 14.","DOI":"10.3390\/cancers14061454"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: Clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s10020-018-0051-4","article-title":"Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics","volume":"24","author":"Runcie","year":"2018","journal-title":"Mol. Med."},{"key":"ref_70","first-page":"319","article-title":"Recombinant bispecific antibodies for cellular cancer immunotherapy","volume":"9","author":"Muller","year":"2007","journal-title":"Curr. Opin. Mol. Ther."},{"key":"ref_71","first-page":"182","article-title":"Dual targeting strategies with bispecific antibodies","volume":"4","author":"Kontermann","year":"2012","journal-title":"Money Advice Budg. Serv."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00063030-200923020-00003","article-title":"Strategies to extend plasma half-lives of recombinant antibodies","volume":"23","author":"Kontermann","year":"2009","journal-title":"BioDrugs"},{"key":"ref_73","first-page":"113","article-title":"Influence of molecular size on tissue distribution of antibody fragments","volume":"8","author":"Li","year":"2016","journal-title":"Money Advice Budg. Serv."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Murati, A., Brecqueville, M., Devillier, R., Mozziconacci, M.J., Gelsi-Boyer, V., and Birnbaum, D. (2012). Myeloid malignancies: Mutations, models and management. BMC Cancer, 12.","DOI":"10.1186\/1471-2407-12-304"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/BS9.0000000000000024","article-title":"Will immune therapy cure acute myeloid leukemia?","volume":"1","author":"Gale","year":"2019","journal-title":"Blood Sci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2362.2007.01746.x","article-title":"Expression of the target receptor cd33 in cd34+\/cd38\u2212\/cd123+ aml stem cells","volume":"37","author":"Hauswirth","year":"2007","journal-title":"Eur. J. Clin. Invest."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/mpo.2950200303","article-title":"Expression of myeloid differentiation antigens in acute nonlymphocytic leukemia: Increased concentration of cd33 antigen predicts poor outcome\u2014A report from the childrens cancer study group","volume":"20","author":"Dinndorf","year":"1992","journal-title":"Med. Pediatr. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1080\/10428190903050013","article-title":"Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: A phase 1 trial","volume":"50","author":"Raza","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1200\/JCO.2005.09.133","article-title":"Phase iii randomized multicenter study of a humanized anti-cd33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia","volume":"23","author":"Feldman","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3324\/haematol.2012.066613","article-title":"Randomized phase iib study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia","volume":"98","author":"Sekeres","year":"2013","journal-title":"Haematologica"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/blood-2015-11-680546","article-title":"Decitabine enhances anti-cd33 monoclonal antibody bi 836858-mediated natural killer adcc against aml blasts","volume":"127","author":"Vasu","year":"2016","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2002-03-0852","article-title":"Elevated expression of il-3ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis","volume":"100","author":"Testa","year":"2002","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.3109\/10428194.2014.956316","article-title":"A phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-cd123 monoclonal antibody csl360 in relapsed, refractory or high-risk acute myeloid leukemia","volume":"56","author":"He","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1182\/blood.V124.21.120.120","article-title":"First-in man, phase 1 study of csl362 (anti-il3r\u03b1\/anti-cd123 monoclonal antibody) in patients with cd123+ acute myeloid leukemia (aml) in cr at high risk for early relapse","volume":"124","author":"Smith","year":"2014","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41375-020-0773-5","article-title":"Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: Results from a multicenter, randomized, phase 2\/3 study","volume":"35","author":"Montesinos","year":"2021","journal-title":"Leukemia"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.3324\/haematol.2018.192757","article-title":"Cd38 as a therapeutic target for adult acute myeloid leukemia and t-cell acute lymphoblastic leukemia","volume":"104","author":"Naik","year":"2019","journal-title":"Haematologica"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3324\/haematol.2019.242974","article-title":"Daratumumab inhibits acute myeloid leukaemia metabolic capacity by blocking mitochondrial transfer from mesenchymal stromal cells","volume":"106","author":"Mistry","year":"2021","journal-title":"Haematologica"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"7358","DOI":"10.4049\/jimmunol.180.11.7358","article-title":"Human flt3 is expressed at the hematopoietic stem cell and the granulocyte\/macrophage progenitor stages to maintain cell survival","volume":"180","author":"Kikushige","year":"2008","journal-title":"J. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nrc1169","article-title":"The role of flt3 in haematopoietic malignancies","volume":"3","author":"Stirewalt","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"7059","DOI":"10.1200\/jco.2015.33.15_suppl.7059","article-title":"Efficacy and safety of an anti-flt3 antibody (ly3012218) in patients with relapsed acute myeloid leukemia","volume":"33","author":"Sanford","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-023-01490-w","article-title":"Phase i study evaluating the fc-optimized flt3 antibody flysyn in aml patients with measurable residual disease","volume":"16","author":"Heitmann","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_93","first-page":"1490","article-title":"Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.leukres.2006.07.005","article-title":"Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (sos): An overview from the research on adverse drug events and reports (radar) project","volume":"31","author":"McKoy","year":"2007","journal-title":"Leuk. Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood.V99.7.2310","article-title":"Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (mylotarg) therapy","volume":"99","author":"Rajvanshi","year":"2002","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (alfa-0701): A randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1182\/blood.V118.21.79.79","article-title":"Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of aml patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the goelams aml 2006 ir study","volume":"118","author":"Delaunay","year":"2011","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3324\/haematol.2016.141937","article-title":"Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: A comparison of 3 mg\/m2 with 6 mg\/m2 in the ncri aml17 trial","volume":"101","author":"Burnett","year":"2016","journal-title":"Haematologica"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2012.42.2964","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia","volume":"30","author":"Burnett","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","article-title":"Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: Results of the randomized phase iii eortc-gimema aml-19 trial","volume":"34","author":"Amadori","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/blood.2023020630","article-title":"Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with aml: The uk ncri aml18 trial","volume":"142","author":"Freeman","year":"2023","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Xu, Q., He, S., and Yu, L. (2021). Clinical benefits and safety of gemtuzumab ozogamicin in treating acute myeloid leukemia in various subgroups: An updated systematic review, meta-analysis, and network meta-analysis. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.683595"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood.2019003471","article-title":"Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia","volume":"135","author":"Fournier","year":"2020","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/bjh.19967","article-title":"Cpx-351 +\/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, flt3-itd negative, aml: A pilot study","volume":"206","author":"Ganzel","year":"2025","journal-title":"Br. J. Haematol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1182\/blood-2001-12-0174","article-title":"Experience with gemtuzumab ozogamycin (\u201cmylotarg\u201d) and all-trans retinoic acid in untreated acute promyelocytic leukemia","volume":"99","author":"Estey","year":"2002","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2008.18.6130","article-title":"Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin","volume":"27","author":"Ravandi","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood-2013-03-491506","article-title":"Sgn-cd33a: A novel cd33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant aml","volume":"122","author":"Walter","year":"2013","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2018-03-841171","article-title":"A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with cd33-positive aml","volume":"132","author":"Fathi","year":"2018","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood-2017-06-789800","article-title":"A phase 1 trial of vadastuximab talirine as monotherapy in patients with cd33-positive acute myeloid leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"TPS7066","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS7066","article-title":"Cascade: A phase 3, randomized, double-blind study on vadastuximab talirina versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"35","author":"Wang","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1158\/1535-7163.MCT-17-1077","article-title":"Imgn779, a novel cd33-targeting antibody-drug conjugate with DNA-alkylating activity, exhibits potent antitumor activity in models of aml","volume":"17","author":"Kovtun","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1182\/blood.V124.21.2321.2321","article-title":"The antibody-drug conjugate (adc) imgn779 is highly active in vitro and in vivo against acute myeloid leukemia (aml) with flt3-itd mutations","volume":"124","author":"Whiteman","year":"2014","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2018-99-112891","article-title":"Maturing clinical profile of imgn779, a next-generation cd33-targeting antibody-drug conjugate, in patients with relapsed or refractory acute myeloid leukemia","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/protein\/13.8.575","article-title":"Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor","volume":"13","author":"Frankel","year":"2000","journal-title":"Protein Eng."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/bloodadvances.2023011721","article-title":"Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia","volume":"8","author":"Lane","year":"2024","journal-title":"Blood Adv."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1470-2045(23)00674-5","article-title":"Pivekimab sunirine (imgn632), a novel cd123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: A phase 1\/2 study","volume":"25","author":"Daver","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"14792","DOI":"10.1074\/jbc.M313127200","article-title":"Identification and characterization of a novel human myeloid inhibitory c-type lectin-like receptor (micl) that is predominantly expressed on granulocytes and monocytes","volume":"279","author":"Marshall","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1182\/blood-2007-03-083048","article-title":"The novel aml stem cell associated antigen cll-1 aids in discrimination between normal and leukemic stem cells","volume":"110","author":"Kelder","year":"2007","journal-title":"Blood"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13045-019-0726-5","article-title":"Targeting cll-1 for acute myeloid leukemia therapy","volume":"12","author":"Ma","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"E175","DOI":"10.1002\/ajh.26136","article-title":"A phase i dose-escalation study of dcll9718s, an antibody-drug conjugate targeting c-type lectin-like molecule-1 (cll-1) in patients with acute myeloid leukemia","volume":"96","author":"Daver","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_123","first-page":"3806","article-title":"Ags62p1, a novel anti-flt3 antibody drug conjugate, employing site specific conjugation, demonstrates preclinical anti-tumor efficacy in aml tumor and patient derived xenografts","volume":"76","author":"Lowe","year":"2016","journal-title":"Blood"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41375-024-02510-5","article-title":"Effective eradication of acute myeloid leukemia stem cells with flt3-directed antibody-drug conjugates","volume":"39","author":"Able","year":"2025","journal-title":"Leukemia"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2007.08.005","article-title":"Interleukin-2 receptor signaling in regulatory t cell development and homeostasis","volume":"114","author":"Burchill","year":"2007","journal-title":"Immunol. Lett."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.ejca.2009.02.021","article-title":"Interleukin-2 receptor alpha-chain (cd25) expression on leukaemic blasts is predictive for outcome and level of residual disease in aml","volume":"45","author":"Terwijn","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/bjh.12109","article-title":"Expression of cd25 independently predicts early treatment failure of acute myeloid leukaemia (aml)","volume":"160","author":"Cerny","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"106385","DOI":"10.1016\/j.leukres.2020.106385","article-title":"Camidanlumab tesirine, an antibody-drug conjugate, in relapsed\/refractory cd25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase i study","volume":"95","author":"Goldberg","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"Cac10-vcmmae, an anti-cd30-monomethyl auristatin e conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3109\/10428194.2012.728596","article-title":"Cd30 expression in acute myeloid leukemia is associated with flt3-internal tandem duplication mutation and leukocytosis","volume":"54","author":"Fathi","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.clml.2012.12.006","article-title":"Cd30 expression in high-risk acute myeloid leukemia and myelodysplastic syndromes","volume":"13","author":"Zheng","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/cncr.32657","article-title":"A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with cd30-expressing relapsed\/refractory acute myeloid leukemia","volume":"126","author":"Narayan","year":"2020","journal-title":"Cancer"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Scalise, M., Pochini, L., Console, L., Losso, M.A., and Indiveri, C. (2018). The human slc1a5 (asct2) amino acid transporter: From function to structure and role in cell biology. Front. Cell Dev. Biol., 6.","DOI":"10.3389\/fcell.2018.00096"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejphar.2018.07.007","article-title":"The role of asct2 in cancer: A review","volume":"837","author":"Liu","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"LB-295","DOI":"10.1158\/1538-7445.AM2018-LB-295","article-title":"Medi7247, a novel pyrrolobenzodiazepine adc targeting asct2 with potent in vivo activity across a spectrum of hematological malignancies","volume":"78","author":"Monks","year":"2018","journal-title":"Cancer Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s11523-024-01054-z","article-title":"Asct2-targeting antibody-drug conjugate medi7247 in adult patients with relapsed\/refractory hematological malignancies: A first-in-human, phase 1 study","volume":"19","author":"Maris","year":"2024","journal-title":"Target. Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/nbt1141","article-title":"Arming antibodies: Prospects and challenges for immunoconjugates","volume":"23","author":"Wu","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0145-2126(01)00096-0","article-title":"In vitro testing of the leukaemia monoclonal antibody wm-53 labeled with alpha and beta emitting radioisotopes","volume":"26","author":"Henniker","year":"2002","journal-title":"Leuk. Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood.V94.4.1237","article-title":"Phase i study of (131)i-anti-cd45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome","volume":"94","author":"Matthews","year":"1999","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1182\/blood-2005-06-2317","article-title":"131i-anti-cd45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission","volume":"107","author":"Pagel","year":"2006","journal-title":"Blood"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"5444","DOI":"10.1182\/blood-2009-03-213298","article-title":"Allogeneic hematopoietic cell transplantation after conditioning with 131i-anti-cd45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"114","author":"Pagel","year":"2009","journal-title":"Blood"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1182\/blood-2014-12-617019","article-title":"Anti-cd45 radioimmunotherapy without tbi before transplantation facilitates persistent haploidentical donor engraftment","volume":"127","author":"Orozco","year":"2016","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.bbmt.2014.05.014","article-title":"Radiolabeled anti-cd45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome","volume":"20","author":"Mawad","year":"2014","journal-title":"Biol. Blood Marrow. Transpl."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1200\/JCO.23.02018","article-title":"Randomized phase iii sierra trial of (131)i-apamistamab before allogeneic hematopoietic cell transplantation versus conventional care for relapsed\/refractory aml","volume":"43","author":"Gyurkocza","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1158\/1078-0432.CCR-10-0382","article-title":"Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia","volume":"16","author":"Rosenblat","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"7050","DOI":"10.1200\/jco.2015.33.15_suppl.7050","article-title":"Phase i trial of alfa-particle therapy with actinium-225 (225-ac)-lintuzumab (anti-cd33) and low dose cytarabine (ldac) in older patients with untreated acute myeloid leukemia","volume":"33","author":"Jurcic","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e522","DOI":"10.1038\/bcj.2017.2","article-title":"Acute myeloid leukemia targets for bispecific antibodies","volume":"7","author":"Hoseini","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"101219","DOI":"10.1016\/j.beha.2020.101219","article-title":"Cd123 bi-specific antibodies in development in aml: What do we know so far?","volume":"33","author":"Slade","year":"2020","journal-title":"Best Pr. Res. Clin. Haematol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/s41375-019-0645-z","article-title":"Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk mds or aml patients failing hypomethylating agents","volume":"34","author":"Kubasch","year":"2020","journal-title":"Leukemia"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood-2023-187721","article-title":"A phase 1 study of cd38-bispecific antibody (xmab18968) for patients with cd38 expressing relapesed\/refractoryacute myeloid leukemia","volume":"142","author":"Murthy","year":"2023","journal-title":"Blood"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/14737140.2024.2373888","article-title":"First-in-human clinical trial results with abbv-184, a first-in-class t-cell receptor\/anti-cd3 bispecific protein, in adults with previously treated aml or nsclc","volume":"24","author":"Peterlin","year":"2024","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2020-136398","article-title":"Gtb-3550 trike\u2122 for the treatment of high-risk myelodysplastic syndromes (mds) and refractory\/relapsed acute myeloid leukemia (aml) safely drives natural killer (nk) cell proliferation at initial dose cohorts","volume":"136","author":"Warlick","year":"2020","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/01.HS9.0000561788.84381.2e","article-title":"S877 safety and clinical activity of amv564, a cd33\/cd3 t-cell engager, in patients with relapsed\/refractory acute myeloid leukemia (aml): Updated results from the phase 1 first-in human trial","volume":"3","author":"Westervelt","year":"2019","journal-title":"HemaSphere"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/10428194.2024.2346755","article-title":"Safety and tolerability of amg 330 in adults with relapsed\/refractory aml: A phase 1a dose-escalation study","volume":"65","author":"Ravandi","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"e13742","DOI":"10.1111\/cts.13742","article-title":"First-in-human study of jnj-67571244, a cd33 x cd3 bispecific antibody, in relapsed\/refractory acute myeloid leukemia and myelodysplastic syndrome","volume":"17","author":"Narayan","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1182\/blood-2021-149337","article-title":"Tolerability and single agent anti-neoplastic activity of the cd3xcd123 bispecific antibody apvo436 in patients with relapsed\/refractory aml or mds","volume":"138","author":"Watts","year":"2021","journal-title":"Blood"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"6492","DOI":"10.1182\/bloodadvances.2023010956","article-title":"Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed\/refractory acute myeloid leukemia","volume":"7","author":"Ravandi","year":"2023","journal-title":"Blood Adv."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"114260","DOI":"10.1016\/j.celrep.2024.114260","article-title":"Immunotherapeutic targeting of surfaceome heterogeneity in aml","volume":"43","author":"Bordeleau","year":"2024","journal-title":"Cell Rep."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Xu, S. (2024). Bispecific antibody (abl602 2 + 1) induced bistable acute myeloid leukemia kinetics. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-75971-4"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/10\/4571\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:30:32Z","timestamp":1760031032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/10\/4571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,10]]},"references-count":160,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["ijms26104571"],"URL":"https:\/\/doi.org\/10.3390\/ijms26104571","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,10]]}}}